Document:

EX-4.5.2

 Exhibit 4.5.2 

CONFIDENTIAL TREATMENT REQUESTED BY CELLECTIS S.A.—CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE
COMMISSION. 
 EXECUTION COPY 

Amendment No. 2 to the Product Development, Option, License and Commercialization Agreement 

This Second Amendment (the “Amendment”) to the Research, Product Development, Option, License and Commercialization Agreement
effective as of February 17, 2014 (as amended, the “Agreement”) is dated as of and shall become effective as of the November 28th, 2016 (hereinafter the “Effective
Date”) by and between Les Laboratoires Servier, a corporation incorporated under the laws of France having a principal place of business at 50 rue Carnot, 92150 Suresnes, France (“LLS”) and Institut de Recherches
Internationales Servier, a corporation incorporated under the laws of France having its principal place of business at 50 rue Carnot, 92 150 Suresnes, France (“IRIS”) (LLS and IRIS being together referred to as
“Servier”), and Cellectis SA, a company incorporated under the laws of France having a principal place of business, at 8, rue de la Croix Jarry, 75013 Paris, France (“Cellectis”). Cellectis and Servier are
individually referred to herein as a “Party” and collectively as the “Parties.” 
 WHEREAS, in furtherance
of, and as part of, the transactions contemplated by the Agreement, subject to the terms and conditions set forth in this Amendment, Cellectis desires to clarify the grant of certain rights to Servier; 

WHEREAS, pursuant to the Agreement, Cellectis granted certain exclusive patent rights to Servier on the terms set forth therein in respect of,
among other things, the Servier Products in the Field; 
 WHEREAS, pursuant to the Research Collaboration and License Agreement dated as of
June 17, 2014 by and between Pfizer, Inc. (“Pfizer”) and Cellectis (as amended from time to time, the “Pfizer Collaboration Agreement”), Cellectis granted certain exclusive patent rights to Pfizer on the terms
set forth therein in respect of, among other things, the Pfizer Products in the Pfizer Product Field; 
 WHEREAS, in furtherance of, and as
part of, the transactions contemplated by the Exclusive License and Collaboration Agreement dated as of October 30, 2016 by and between Servier and Pfizer (the “Pfizer-Servier Agreement”)
and pursuant to the terms set forth therein, Pfizer has directed that Cellectis license certain patent rights to Servier in respect of the Pfizer Products in the Pfizer Product Field in the Servier Territory; and 

WHEREAS, the parties desire to amend the Agreement as set forth below. 

NOW, THEREFORE, for valuable consideration, the receipt of which is hereby acknowledged, the Parties hereto agree as follows: 

All capitalized terms used in this Amendment and not otherwise defined have the meanings assigned to them in the Agreement. 

  
 1 

 1. Definitions. 

The Parties agree to add the following definitions in Article 1 of the Agreement: 

“Pfizer Product Field” means human anti-tumor adoptive immunotherapy. 

“Pfizer Product” means an allogeneic anti-tumor adoptive T-cell expressing a single
chain chimeric antigen receptor (CAR) targeting [***], and including specific attributes, as initially developed by Cellectis as per the Pfizer Collaboration Agreement, and that are initially licensed by Cellectis to Pfizer as per the Pfizer
Collaboration Agreement. 
 “Pfizer Territory” means the United States of America and its territories and possessions. 

“Servier Product” means UCART19 [***], corresponding to an allogeneic anti-tumor adoptive
T-cell expressing a single chain chimeric antigen receptor (CAR) directed against [***] target, and including specific attributes, as initially developed by Cellectis as per the Agreement, and that are
initially licensed by Cellectis to Servier as per the Agreement together with any additional allogeneic anti-tumor adoptive T-cell CARs that bind to [***] as may be optioned by Servier from Cellectis under
this Agreement. 
 “Servier Sublicensee” means a sublicensee of Servier pursuant to the Agreement, which, for the avoidance
of doubt, does not include any sublicense to the [***] Cellectis Patents not owned by Cellectis and/or the University of Minnesota. 

“Servier Territory” means the world other than the Pfizer Territory. 

“[***] Cellectis Patents” means the patent and patent applications listed in Exhibit A of this Amendment. 

The definition for “Cellectis Patents” in Subsection 1.10 is replaced with the following: 

“Cellectis Patents” means all Patents that are Controlled by Cellectis and its Affiliates at the Effective Date and
thereafter during the Term and that Cover, or would be reasonably necessary or useful for, the Development, Manufacture or Commercialization of Pre-Candidate Product(s), Candidate Product(s), or Product(s), as
appropriate, (including its composition, formulation, combination, product by process, or method of use, manufacture, preparation or administration). Cellectis Patents shall include Cellectis’ interest in Joint Patents that meet the above
requirements, and in any event shall include [***] Cellectis Patents and those other Patents set forth on Exhibit 2. 
 2. Exhibit A. 

Exhibit A is added to the Agreement. 
  

[***] CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION 

  
 2 

 3. License Grant. 

The Parties hereby agree to remove and replace Section 4.2 with the following: 

4.2 Servier Rights and Obligations upon Exercise of Option. 

(a)    Exclusive License. Upon Servier’s exercise of its Option to License for a given Product, Cellectis shall grant
to Servier during the Term an exclusive (even as to Cellectis), worldwide license with the right to grant sublicenses, under the Cellectis IP (but specifically excluding the [***] Cellectis Patents) to Develop, have Developed, manufacture, have
manufactured, and Commercialize said Product in the Field. 
 (b)    With respect to each Product elected by Servier,
through its Option to License, Servier will assume full responsibility, at its expenses, for the further Development, manufacture and Commercialization of such Product in the Field. 

(c)    Upon Servier’s exercise of the Option to License for a given Product, Servier will use, and will ensure that
its Affiliates, Sublicensees, and subcontractors use Commercially Reasonable Efforts in Developing and Commercializing the corresponding Product in the Targeted Indications and the Targeted Territory, and are in compliance with this Agreement. 

(d)    Upon Servier’s exercise of its Option to License for a given Product and subject to the terms and conditions of
the Agreement, Cellectis hereby grants to Servier and its Affiliates, on a country by country basis throughout the world (i) the right to use the [***] engineered by Cellectis pursuant to this Agreement for Development of the Product, until the
filing of the corresponding IND or IMPD (or foreign equivalent), and (ii) after the IND or IMPD filing, an exclusive (even as to Cellectis) license to the [***] Cellectis Patents to use the [***] engineered by Cellectis to make, have made, use,
have used, sell, have sold, offer for sale, have offered for sale, import, have imported, and otherwise exploit and Commercialize such Product, without the right to grant sublicenses, provided that Servier may sublicense solely in relation to a
transaction involving, with respect to all [***] Cellectis Patents, only the [***] Cellectis Patents owned by Cellectis and/or owned by University of Minnesota. Notwithstanding the foregoing, Servier hereby acknowledges and agrees that, at
Servier’s direction, Cellectis shall have the right and obligation to promptly and diligently grant licenses and rights under the [***] Cellectis Patents to Pfizer or subcontractor designated by Pfizer, or any other third party designated by
Pfizer and agreed to by Servier, in respect of the Servier Products in the Field in the Pfizer Territory, and Servier’s license and other rights under the [***] Cellectis Patents shall be limited accordingly so long as the relevant licenses in
this Agreement (or any other relevant licenses entered into pursuant to the terms thereof) remain in effect. For the sake of clarity and notwithstanding anything to the contrary in this Agreement, the license granted to Servier by Cellectis herein
does not give Servier the right (i) to [***] or (ii) to sublicense the [***] Cellectis Patents other than in relation to a transaction involving, with respect to all [***] Cellectis Patents, only the [***] Cellectis Patents owned by
Cellectis and/or owned by University of Minnesota. 
 (e)    Upon exercise of the Option to License on a Product-by-Product basis, and upon Servier’s written direction, Cellectis shall have the right and obligation to promptly and diligently grant a direct license, on a
country by country and Product by Product basis, under the [***] Cellectis Patents to any Servier Sublicensee, provided that the grant of such license to the extent involving [***] Cellectis Patents licensed to Cellectis by Life Technologies
Corporation, must include a license in respect of all of the [***] Cellectis Patents and will (i) correspondingly limit the license grants to Servier in Section 4.2(d), and (ii) provide the Servier Sublicensee with a similar right to
obtain a direct license from 
  
 [***] CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY
FILED WITH THE COMMISSION 

  
 3 

 
Cellectis consistent with, and to the extent of, the sublicense rights the Servier Sublicensee otherwise receives from Servier with respect to the Cellectis Patents other than the [***] Cellectis
Patents, provided that the grant of such direct license will correspondingly limit such license grants to such Servier Sublicensee. Cellectis shall promptly and diligently execute a license agreement with Servier and such Servier Sublicensee for the
purpose of granting such license to the Servier Sublicensee and limiting the corresponding license grant to Servier in Section 4.2(d). The parties hereby acknowledge that any such negotiations would be solely to limit Servier’s rights
herein for the benefit of such Servier Sublicensee and, as such, the parties agree and acknowledge that no additional consideration would be due to Cellectis as no additional rights would be granted. The parties further agree and acknowledge that
all consideration due to Cellectis under the Agreement has been valued fairly and equitably in good faith, and would not be reduced or otherwise amended because of any limitation of Servier’s rights for the benefit of a Servier Sublicensee. The
parties acknowledge and agree that any rights or licenses that may hereafter be granted by Cellectis at the written direction of Servier as contemplated by this Section 4.2(e) are rights or licenses that were provided to Servier pursuant to
this Agreement in accordance with the broad collaboration and development activities contemplated by the Agreement, and therefore Cellectis has already received (or, in the future and in accordance with the terms of this Agreement, will have the
right to receive) compensation that Cellectis and Servier have determined is fair and equitable and that Cellectis shall therefore not have the right to any additional compensation from Servier or any other person or entity in connection with the
foregoing. 
 The Parties hereby agree to insert the following Section 4.3: 

4.3 Rights Among Cellectis, Servier and Pfizer. 

(a)    Subject to the terms of this Agreement, at the written direction of Pfizer and in furtherance of and pursuant to the
Pfizer Collaboration Agreement and the transactions contemplated thereby on a Pfizer Product-by-Pfizer Product basis, Cellectis hereby grants to Servier and its
Affiliates (i) the right to use the [***] engineered by Cellectis pursuant to the Pfizer Collaboration Agreement to develop Pfizer Products, until, in each case, the filing of an IND for each Pfizer Product as directed by Pfizer, in the Pfizer
Product Field, in the Servier Territory, and (ii) a fully paid-up and royalty free (with respect to Cellectis), exclusive (even as to Cellectis) license under the [***] Cellectis Patents, to make, have
made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize such Pfizer Product, in each case solely in the Pfizer Product Field in the Servier Territory, without the
right to grant sublicenses, provided that Servier may sublicense solely in relation to a transaction involving, with respect to all [***] Cellectis Patents, only the [***] Cellectis Patents owned by Cellectis and/or owned by University of Minnesota,
and Cellectis shall further have the obligation to grant licenses and rights under the [***] Cellectis Patents to subcontractors as directed by Servier, and to other third parties as directed by Servier and agreed to by Pfizer, pursuant to and as
contemplated by the Pfizer-Servier Agreement in respect of the Pfizer Products (as directed in writing by Pfizer) in the Pfizer Product Field in the Servier Territory, and Servier’s license and other
rights under the [***] Cellectis 
  
 [***] CONFIDENTIAL MATERIAL REDACTED AND
SEPARATELY FILED WITH THE COMMISSION 

  
 4 

 
Patents shall be limited accordingly so long as the relevant licenses in the Pfizer Collaboration Agreement (or any other relevant licenses entered into pursuant to the terms thereof) remain in
effect. For sake of clarity, the license granted to Servier by Cellectis herein does not give Servier the right to [***]. For further sake of clarity, Servier does not have the right to grant any sublicenses in respect of the rights licensed to it
pursuant to Section 4.3(a) herein other than in relation to a transaction involving, with respect to all [***] Cellectis Patents, only the [***] Cellectis Patents owned by Cellectis and/or owned by University of Minnesota, and any purported
sublicense so made by Servier shall be null and void ab initio, provided that the foregoing is without limitation of Servier’s rights that are set forth in Section 4.2(e) hereof. 

(b)    Servier hereby consents to the license directed by Servier and granted by Cellectis to Pfizer pursuant to the Pfizer
Collaboration Agreement, as amended, and the licenses that may hereafter be granted by Cellectis at the written direction of Pfizer as agreed to by Servier pursuant to the terms thereof. The parties acknowledge and agree that any rights or licenses
that have been granted to Pfizer at Servier’s written direction to Cellectis (including any expansions of such rights or licenses, pursuant to this Agreement, that Servier directs Cellectis in writing to grant to Pfizer), or that may hereafter
be granted by Cellectis at the written direction of Pfizer and agreed to by Servier relating to those same rights granted to Pfizer, are rights or licenses that were provided to Servier pursuant to this Agreement in accordance with the broad
collaboration and development activities contemplated hereunder, and therefore Cellectis has already received (or, in the future and in accordance with the terms of this Agreement, will have the right to receive) compensation that Cellectis and
Servier have determined is fair and equitable and that Cellectis shall therefore not have the right to any additional payments or compensation from Pfizer, Servier or any other person or entity in connection with the foregoing. Without limiting the
foregoing, the parties agree and acknowledge that all consideration paid or to be paid, whether one-time payments, milestone payments, royalty payments or otherwise, to Cellectis under the Pfizer Collaboration
Agreement or this Agreement shall not be reduced or otherwise modified or amended because of the license granted to Pfizer or other third parties as contemplated hereby. 

(c)    The parties further acknowledge and agree that any rights or licenses that have been granted by Cellectis to Pfizer
at Servier’s written direction to Cellectis (including any expansions of such rights or licenses, pursuant to this Agreement, that Servier directs Cellectis in writing to grant to Pfizer), or that may hereafter be granted by Cellectis at the
written direction of Pfizer and agreed to by Servier relating to those same rights granted to Pfizer, shall terminate on a Servier Product-by-Servier Product basis upon
the earlier to occur of (i) termination or expiration of the license granted by Cellectis to Servier in respect of the [***] Cellectis Patents in further respect of a Servier Product pursuant to this Agreement, or (ii) on a Servier Product-by-Servier Product basis, termination or expiration of the license granted by Servier to Pfizer in respect of a Servier Product pursuant to the Pfizer-Servier Agreement (as amended from time to time). 
  

[***] CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION 

  
 5 

 The Parties hereby agree to remove and replace Section (III)(a) of the Agreement with the following: 

Subject to entry into force of the Amendment, Cellectis hereby grants to Servier a license in respect of the rights set forth in
Section 4.2 for the UCART19 Product [***] as per the terms of Section 4.2 of the Agreement. 
 4. Termination. 

The Parties hereby agree to remove and replace Section 11.1 with the following: 

11.1 Term. 

(a)    This Agreement will become effective as of the Effective Date and, unless earlier terminated pursuant to the
provisions of Sections 11.1(b), 11.2 or 12.2.3, will expire upon the later to occur of the last sales of the Product or the Pfizer Product, provided that all rights and licenses granted by Cellectis to Servier pursuant to Section 4.3(a), and
subject to Section 11.l(b), all obligations to which the parties are bound hereunder with relation thereto, will continue in force and effect, to the extent such rights and licenses were not previously or concurrently terminated and will
subsequently terminate in accordance with the terms of the Pfizer Collaboration Agreement wherein such rights and licenses were initially granted to Pfizer. Upon expiration of the Royalty Term with respect to a Product, the licenses granted by
Cellectis to Servier under this Agreement with respect to such Product shall remain in effect as granted in accordance with this Agreement but become fully paid-up, royalty-free licenses until termination or
expiration of this Agreement. 
 (b)    The license granted pursuant to Section 4.3(a) herein shall terminate
immediately upon the earlier to occur of (i) on a Pfizer Product-by-Pfizer Product basis, termination or expiration of the license granted by Cellectis to Pfizer in
respect of the [***] Cellectis Patents in further respect of a Pfizer Product pursuant to the Pfizer Collaboration Agreement, or (ii) on a Pfizer Product-by-Pfizer
Product basis, termination or expiration of the license granted by Pfizer to Servier in respect of a Pfizer Product pursuant to the Pfizer-Servier Agreement (as amended from time to time). 

5. No other revisions. 
 Except as expressly set forth in
this Amendment, the other provisions of the Agreement remain unchanged and continue in full force and effect. To the extent that the provisions of this Amendment conflict with what is set forth in the Agreement, the provisions of this Amendment
shall take precedence. All disputes arising out of or in connection with this Amendment, unless otherwise specified in the Agreement, shall be resolved in accordance with the principles set forth in article 13.2 of the Agreement. 

 
 [***] CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION 

  
 6 

 IN WITNESS WHEREOF, the Parties have caused this Amendment to the Product Development, Option, License and
Commercialization Agreement to be executed by their duly authorized representatives. 
 Made in Paris, on November 28th, 2016 

 

													
	For Cellectis SA	 		 	For Les Laboratoires Servier,
					
	By:	 	 /s/ Andre Choulika
	 		 	By:	 	 /s/ Christian Bazantay

		 	Name:	 	Andre CHOULIKA	 		 		 	Name:	 	Christian BAZANTAY
		 	Title:	 	Chief Executive Officer	 		 		 	Title:	 	Proxy
						
		 		 		 		 	By:	 	 /s/ Eric Falcand

		 		 		 		 		 	Name:	 	Eric FALCAND
		 		 		 		 		 	Title:	 	Proxy
					
	For Institut de Recherches Internationales Servier	 		 		 		 	
						
	By:	 	 /s/ Emmanuel Canet
	 		 		 		 	
		 	Name:	 	Dr. Emmanuel CANET	 		 		 		 	
		 	Title:	 	President of R&D	 		 		 		 	

  
 7 

 Exhibit A 

[***] 
  

[***] CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION 

  
 8EX-4.6.3

 Exhibit 4.6.3 

CONFIDENTIAL TREATMENT REQUESTED BY CELLECTIS S.A.—CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE
COMMISSION. 
  

			
	Execution Copy	  	 OTC Agreement Number: A20110394

Case Number: 20100004
 Cellectis Ref: CLS-12024-AM03

 THIRD AMENDMENT 

TO EXCLUSIVE PATENT LICENSE AGREEMENT (“EPLA”) 

THIS THIRD AMENDMENT TO EXCLUSIVE PATENT LICENSE AGREEMENT (the “Third Amendment”) is made and entered effective as of the
date of the last signature (the “Third Amendment Effective Date”), by and between Regents of the University of Minnesota (the “University”), a Minnesota constitutional corporation under the laws of the state of Minnesota,
and Cellectis SA, a Corporation under the laws of the France having a place of business at 8, rue de la Croix Jarry, 75013 Paris, France (the “Licensee”) each a “Party” and collectively, the “Parties”). 

BACKGROUND 
 The Parties
entered into the EPLA on January 10, 2011 and subsequently amended it under the First Amendment to the EPLA, dated May 24, 2012 and March 27, 2014. The Parties wish to further amend the EPLA as indicated below. 

NOW, THEREFORE, THE PARTIES AGREE AS FOLLOWS: 

1.    Upfront Payment. Licensee shall pay to University One Million Dollars ($1,000,000) as follows: Eight Hundred Thousand Dollars
($800,000) upon execution of this Third Amendment; and the remaining Two Hundred Thousand ($200,000) upon Licensee’s use of a Licensed Product in a clinical trial or eighteen (18) months from the Third Amendment Effective Date., whichever
occurs first. 
 2.    Definition of Affiliate. Section 1.1 of the Exhibit A Terms and Conditions of the EPLA is hereby
revised by changing “ten percent (10%)” to “fifty percent (50%)” in the second sentence. 
 3.    Field(s) of
Use. Section 2 of the EPLA is hereby deleted and replaced with the following: 
 “Section 2, Field of Use: Non-Agriculture Field of Use” means all fields except the Agriculture Field of Use. 

Agriculture Field of Use” means any use of the Licensed Technology for engineering and developing plants, for any purpose.”

 4.    Section 11.4 of the EPLA (Running Royalties and Annual Minimums) is revised as follows: 

 

	 	A.	Section 11.4.1 is deleted in its entirety and replaced with the following: 

  
 1/5 

 “11.4.1 Subject to subsection 11.4.3 and payable as provided in
Section 6.4 of the Terms and Conditions, Licensee shall pay to the University royalties on the Net Sales Price of Commercial Sales of Licensed Products (whether sold by Licensee or a Third Party) as follows: 

 

	 	•	 	Agriculture Field of Use. No obligation to pay royalties on the Net Sales Price of Commercial Sales of Licensed Products in the Agriculture Field of Use. 

 

	 	•	 	Non-Agriculture Field of Use. [***] 

  

	 	B.	Section 11.4.2 of the EPLA is hereby deleted. 

  

	 	C.	Section 1141.3 of the EPLA is hereby deleted and replaced with the following: 

“11.4.3 if total royalties paid to University under Section 11.4.1 (Royalties) and under Section 11.5 each
calendar year are less than thirty thousand dollars ($30,000) (“Annual Minimum Royalty), then Licensee shall pay to the University the difference between actual royalties and the Annual Minimum Royalty within forty-five (45) days after the
end of the calendar year.” 
 5.    Section 11.5 (Sublicense Revenues) is hereby deleted in its entirety and replaced with
the following: 
 “11.5 Sublicense Revenue: As determined and payable in Section 6.4 of the Terms and Conditions, the Licensee
shall pay to the University: 
  

	 	•	 	[***] of Bare Sublicense Revenue, and 

  

	 	•	 	[***] of Sublicense Revenue in the Non-Agriculture Field of Use.” 

6.    A new Section 11.6.4 of the EPLA is hereby added: 

“11.6.4 Milestone Payments for revenues obtained by Licensee and/or its Affiliates on Commercial Sales of Licensed Products in the
Agriculture Field of Use; 
  

	 	•	 	When the cumulative revenues received by Licensee and/or its Affiliates on the combined Commercial Sales of Licensed Products reach for the first time $100,000,000, Licensee shall pay to University, [***];

  

	 	•	 	When the cumulative revenues received by Licensee and/or its Affiliates on the combined Commercial Sales of Licensed Products reach for the first time $200,000,000, Licensee shall pay to University, [***]; and

  

	 	•	 	When the cumulative revenues received by Licensee and/or its Affiliates on the combined Commercial Sales of Licensed Products reach for the first time $1,000,000.000 Licensee shall pay to University, [***].

 [***] CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 2/5 

 6.    A new Section 11.11 of the EPLA is hereby added. 

“11.11 Annual Fee. Licensee shall pay to the University an annual fee of One Hundred Fifty Thousand Dollars ($150,000) for the rights
granted under this Agreement for the Agriculture Field of Use. Payment is due on the first day of each calendar year.” 
 7.    A
new Section 11.12 of the EPLA is hereby added. 
 “11.12 Commercialization Fee: Licensee shall pay to the
University [***] per seed containing New Trait(s) developed by Licensee and/or its Affiliates or Third Parties through the use of Licensed Technology that (A) is offered for sale by Licensee and/or its Affiliates or Third Parties in the
Agriculture Field of Use, or (13) is licensed to a Third Party, excluding the following licenses: (l) licenses granted to farmers or grower groups for breeding, seed production and grain production; (2) licenses granted for co-development research projects: or (3) research licenses granted to a Third Party solely for evaluating a trait or variety. For clarity, when several New Traits are licensed together as a combination in a
single seed variety (“Stack”) [***]. “New Trait” means a quality or characteristic that is genetically determined or genetically modified in a crop. For clarity, a New Trait may involve modification of multiple loci in the
genome.” Payment is due upon the occurrence of (A) or (13). 
 8.    Definition of Sublicense Revenue.
Section 1.14 of the Terms and Conditions of the EPLA is deleted in its entirety and replaced with the following: 

“‘Bare Sublicense Revenues’ means all revenue in whatever form earned by the [***]. 

For sake of clarity, the revenues earned by Cellectis in connection with the [***] sublicense granted to Third Parties under the [***], are Sublicense
Revenues”. 
 9.    Section 6.4 (Royalty Payment/Sales Reports) of the Terms and Conditions of the EPLA is deleted in its
entirety and replaced with the following: 
 “Royalty and Sublicense Revenue Payments/Reports.” Within sixty (60) days after
the last day of a calendar quarter during the Term and the Post-termination Period, the Licensee shall deliver to the University a written report in a form acceptable to the University, recounting (i) the number and Net Sales Price amount of of
all sales, leases or other dispositions of Licensed Products, whether made by the Licensee or a sublicensee or Third Party and (ii) receipt of any Sublicense Revenues and/or Bare Sublicense Revenues during such calendar quarter. The Licensee
shall deliver such written report to the University even if no payment is due. The Licensee shall deliver along with such reports, its payment for royalties, Sublicense Revenue and/or Bare Sublicense Revenues owed during such quarter.” 

9.    Right of Assignment to Calyxt Corporation. Section 12.4 of the ‘terms and Conditions of the EPLA is
revised by adding the following sentence at the end of the paragraph: “Notwithstanding the foregoing, Licensee may assign its rights and obligations under this Agreement solely in the Agriculture Field of Use and solely to Calyxt, Inc. upon
written notice to the University and payment of [***], provided at the time of such assignment, Licensee is not in default and Calyxt Inc. agrees (i) to assume all of Licensee’s obligations under the Agreement 

 
 [***] CONFIDENTIAL MATERIAL REDACTED AND SEPARATELY FILED WITH THE COMMISSION. 

  
 3/5 

 
relative to the Agriculture Field of Use; and (ii) to assume fifty (50%) of the Patent Related Expenses. Calyxt, Inc., Licensee, and University shall execute such other documentation to Live
effect to the assignment and reflect the bifurcation of the Field of Use. 
 10.    Except as provided in this Third Amendment, the
terms of the Agreement remain unchanged. Capitalized terms used in this Third Amendment that are not otherwise defined herein have the meanings ascribed to them in the Agreement. 

IN WITNESS WHEREOF, acting through their respective duly authorized representatives, the University and the Licensee have duly
executed, delivered and entered into this Third Amendment as of the Third Amendment Effective Date. 
 [Signature Page Follows] 

  
 4/5 

									
	Regents of the University of Minnesota	 		 	Cellectis S.A.
					
	By:	 	 /s/ Jay Schrankler
	 		 	By:	 	 /s/ André CHOULIKA

	Name:	 	Jay Schrankler	 		 	Name:	 	André CHOULIKA
	Title:	 	Executive Director	 		 	Title:	 	Chief Executive Officer
					
	Date:	 	 12-12-15
	 		 	Date:	 	 December 16, 2015

  
 5/5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]